The deal has still not closed, under a court order or an agreed extension of the hold, per the FTC case page or the court docket
The FTC and 13 states sue to block a $3.5 billion deal they say joins the two largest US vet suppliers
FTC
Request for more information on the merger 20 May 2026
Cencora received an FTC request for more information and documents on the deal1.
FTC
Proposed remedy package from the companies 6 Oct 2026
Covetrus and MWI reportedly offered remedies, and regulators reportedly were not satisfied1.
US District Court, Southern District of New York
FTC and 13 states v. CVET Topco and others 13 Nov 2026
The FTC and the states filed suit to block the deal, and the FTC case page lists it as pending2.
US District Court, Southern District of New York
Temporary restraining order
The companies agreed to an order that keeps them from completing the merger before December 4th, 20263.
The Federal Trade Commission (FTC), the US competition regulator, sued on November 13th, 2026 to block Covetrus from buying MWI Animal Health for $3.5 billion4. Covetrus is a veterinary supply and software company based in Portland, Maine, owned by the private equity firms Clayton, Dubilier & Rice and TPG4,5. MWI is the animal health distribution unit of Cencora, a drug wholesaler based in Conshohocken, Pennsylvania6. The attorneys general of 13 states joined the complaint in federal court in Manhattan7.
The plaintiffs say the two companies are each other's closest rivals and that vets and pet owners would pay more if they merge4. New York's attorney general says the combined company would control more than 50 percent of the relevant markets3. Covetrus says the FTC holds "a narrow and outdated view of the market" and that it will defend the deal in court8.
A judge now decides whether the deal waits for a full ruling. The companies agreed to a temporary restraining order that keeps them from closing before December 4th, 2026, and the states are asking for a preliminary injunction3. For Cencora, J.P. Morgan analysts do not expect the challenge to hurt its forecast7.
The deal faces medium legal and regulatory risk now, and no level is high until a judge rules on the injunction.
LegalMediumA federal suit under the Clayton Act, with a court hold until December 4th, 2026
The states argue the deal breaks Section 7 of the Clayton Act, which bars mergers that may substantially lessen competition9. The companies agreed to a temporary restraining order until December 4th, 20263.
RegulatoryMediumThe FTC calls the deal presumptively unlawful under the 2023 merger guidelines
The FTC says the merger creates highly concentrated markets, which makes it presumptively unlawful under case law and the joint FTC and Justice Department merger guidelines4. The Commission voted 2-0 to authorize the suit4.
EconomicMediumVet clinics could lose one of their two main national suppliers
California says most US veterinary products move through three national suppliers: Covetrus, MWI and Patterson Veterinary9. New York says large clinic groups often buy 65 to 90 percent of their supplies from one company3.
The first test is whether the court hold outlasts December 4th, 2026, and the harder one is whether the companies fight to a ruling or walk away.
Confidence on the mechanism is high: the FTC release, the state releases and the company's statement set out each side's case4,3,8. Confidence on the horizon is medium. No hearing date for the preliminary injunction is public on the FTC case page2.
Analyst assessment. Each call is scored once its date passes.
The FTC announces a settlement that lets the merger close with divestitures, in an FTC press release
Covetrus or Cencora announces that the merger agreement is terminated, in a press release or an SEC filing
- The FTC case page for matter 2610070, updated when filings are posted, for a hearing date or an order2.
- The court docket in the Southern District of New York, for any order on the preliminary injunction.
- Cencora's quarterly and current reports to the Securities and Exchange Commission (SEC), for any change to the deal terms or a termination.
- Covetrus press releases, for a revised remedy offer.
What changed is a filed lawsuit and an agreed court hold, not a ruling on the merits.
The FTC filed for a permanent injunction in the US District Court for the Southern District of New York4. The complaint was filed under seal6. The parties agreed to a temporary restraining order, and the states are now seeking a preliminary injunction3.
Alleged, not decided. The price and service harms are the plaintiffs' allegations. No court has ruled on them yet4,2.
Covetrus says practices can buy from manufacturers, other distributors and online marketplaces. It says those marketplaces are used by more than 60% of US practices and list more than 40 distributors8. Bovine Veterinarian notes these figures are Covetrus's own estimates1.
The deal moved from announcement to lawsuit in nine months, after the companies' remedy offer reportedly failed.
FTCDaniel Guarnera
Director, FTC Bureau of CompetitionHe said Covetrus "wants to eliminate its closest competitor rather than compete for veterinary clinic customers"4.
What to watch
- A hearing date on the preliminary injunction
StatesLetitia James
Attorney General of New YorkHer office says the merged company would control more than 50 percent of the relevant markets3.
What to watch
- The states' request for a preliminary injunction
StatesRob Bonta
Attorney General of CaliforniaHis office says the deal would remove a backup supplier that clinics use during shortages9.
CovetrusBen Wolin
President and CEO, CovetrusAt the announcement he said the combination "is about making animal healthcare more affordable and accessible"5.
What to watch
- Any new remedy offer
CencoraRobert Mauch
President and CEO, CencoraHe said the deal lets Cencora "further invest in our key growth priorities"5.
What to watch
- A termination or another buyer for MWI
Portraits after photographs. Robert Mauch: photo published by cencora.com.
- Court
- Company headquarters
Borders: Natural Earth; state lines: US Census Bureau.
Sources: Covetrus, February 18th, 20265; The Philadelphia Inquirer, November 16th, 20266; American Veterinary Medical Association, March 18th, 202611; Federal Trade Commission, November 13th, 20264
Several numbers in circulation conflict with the primary record, and the price harm is still an allegation.
- California's release speaks of "a multistate coalition of 21 attorneys general"9. The FTC complaint lists 13 states4.
- California's release dates the agreement to March 18th, 20269. Cencora's own announcement is dated February 18th, 20265.
- The FTC calls the two firms the largest suppliers4. New York calls them two of the three largest3. Both describe the same complaint.
- Covetrus's 60% figure for online marketplace use is its own estimate1.
The case tests whether online price comparison counts as competition that can replace a merged-away rival.
The FTC says Vetcove, an online platform where vets compare prices, sharpened the price war between the two firms4. Covetrus uses the same shift to argue the market is open, citing online marketplaces with more than 40 distributors8. The court will weigh which reading fits how clinics buy.
Production animal vets may also feel it. Bovine Veterinarian notes that public information does not show how much the two firms overlap in livestock product distribution1.
Cash and common equity Cencora would receive for MWI
Billions of US dollars, at closing
Source: Covetrus, February 18th, 20265
Cencora would also receive $800 million in preferred equity.
Clinics and their suppliers carry the exposure, and private equity owners carry the deal risk.
Veterinary clinics
Supply prices and service terms
Animal health distribution
Market structure
Private equity
Deal financing and exit plans
Drug wholesale
Cencora's portfolio plans
Readers with exposure to veterinary distribution should plan for the deal to stay on hold into 2027.
- Private equity (PE) and venture capital (VC) firms: expect the court hold to shape exit timelines for animal health assets. Covetrus's planned financing depends on the close10.
- Family offices: treat Cencora's 34.3% stake in a merged company as uncertain until a ruling5.
- Corporates and clinic groups: keep a second supplier. California cites shortages as a reason clinics use two distributors9.
- Law firms: watch the preliminary injunction standard and how the court treats online marketplaces as competitors.
Ask counterparties how they would buy if one national distributor disappeared.
- Supply: what share of your purchases go through Covetrus or MWI, and who is your backup?
- Contracts: do your distributor contracts change on a change of control?
- Pricing: do you compare prices on an online marketplace, and how often do you switch?
- Deal exposure: does any financing or earn-out depend on the merger closing?
We expect the deal to stay on hold through the end of 2026, with a ruling or a walkaway in 2027.
Confidence: medium. The record rests on primary releases from the FTC, two state attorneys general and Covetrus, and wire reports from Reuters and Dow Jones4,9,3,8,7,12. The complaint itself is under seal6, so the market share figures behind the FTC's case are not public.
Primary assessment: the plaintiffs appear to hold the stronger position on concentration, since the FTC calls the deal presumptively unlawful and the companies' earlier remedy offer reportedly did not satisfy regulators4,1.
Strongest alternative: Covetrus may persuade the court that manufacturers, regional distributors and online marketplaces discipline prices8. S&P Global Ratings also describes the market as intensely competitive, naming Patterson and numerous regional players10.
What would make this wrong: a settlement with divestitures before a hearing, or a court order that lets the deal close.
Cencora would keep 34.3% of the combined company, and Covetrus would take on new debt to pay for it.
Cencora would receive $1.25 billion in cash, $800 million in preferred equity and $1.45 billion in common equity, keeping 34.3% of the combined company5. Covetrus planned a $3.05 billion term loan and a $500 million revolving credit line, per S&P Global Ratings, which rates Covetrus CCC+10. Covetrus says it has more than 5,000 employees and over 100,000 customers worldwide5.
These two companies are engaged in fierce head-to-head competition, and Covetrus wants to eliminate its closest competitor rather than compete for veterinary clinic customers.
- FTC Sues to Block $3.5 Billion MWI Animal Health-Covetrus Merger. Bovine Veterinarian, November 13th, 2026
- CVET Topco/MWI Veterinary Supply. Federal Trade Commission, November 13th, 2026
- Attorney General James Sues Nation's Largest Distributors of Veterinary Supplies to Ensure Fair Health Care Prices for Pet Owners. New York Attorney General, November 13th, 2026
- FTC Sues to Block Veterinary Supplies Distributor Covetrus's $3.5 Billion Acquisition of Rival MWI. Federal Trade Commission, November 13th, 2026
- Covetrus and MWI Animal Health to Merge. Covetrus, February 18th, 2026
- Federal Trade Commission sues to block Covetrus' acquisition of Cencora's MWI Animal Health. The Philadelphia Inquirer, November 16th, 2026
- US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus. Reuters, November 13th, 2026
- Covetrus Issues Statement on FTC Decision to Challenge Proposed Merger with MWI Animal Health. Covetrus, November 13th, 2026
- Attorney General Bonta to Keep Corporate Consolidation on a Short Leash, Challenges $3.5 Billion Veterinary Supply Merger. California Attorney General, November 13th, 2026
- Research Update: Covetrus Inc. 'CCC+' Rating Affirmed, Remains On CreditWatch Developing On Merger With MWI Animal Health. S&P Global Ratings, February 25th, 2026
- Covetrus, MWI announce $3.5B merger. American Veterinary Medical Association, March 18th, 2026
- FTC Sues to Block Proposed $3.5 Billion Covetrus-MWI Merger. Dow Jones Newswires, November 13th, 2026